Description

Growth Starter Kit — CJC-1295 + Ipamorelin Bundle

De Growth Starter Kit is the ultimate entry-level bundle for growth hormone testing. This kit combines CJC-1295 — a long-acting GHRH analogue — with Ipamorelin — the most selective GH secretagogue available. As a result, the covers CJC-1295 Ipamorelin bundle both receptor systems of the hypothalamic-pituitary GH axis simultaneously, via two complementary and scientifically well-documented mechanisms.

Moreover, the Growth Starter Kit distinguishes itself through an exceptionally clean hormonal profile. CJC-1295 sustainably prolongs the GH pulse without disrupting physiological pulsatility. Ipamorelin subsequently triggers targeted GH peaks without significant increases in cortisol, ACTH, or prolactin. As a result, the combination offers researchers pure GH effects — without the hormonal noise caused by other secretagogues such as GHRP-6.

What is the Growth Starter Kit?

The Growth Starter Kit is the most widely used dual-receptor growth hormone peptide stack in research. The combination of CJC-1295 and Ipamorelin has been referred to in the scientific literature as the “gold standard” GH secretagogue combination. This is because the two peptides activate separate receptor systems. As a result, together they produce a synergistic GH pulse effect that is greater than what each peptide achieves alone.

Specifically, the protocol works as follows. CJC-1295 activates the GHRH receptor on pituitary somatotropes, thereby widening the GH pulse window. Ipamorelin subsequently activates GHS-R1a (ghrelin receptor) and triggers a sharp, targeted GH release within that extended window. To this end, the two peptides use completely separate intracellular signaling pathways — cAMP/PKA for CJC-1295 and phospholipase C for Ipamorelin — which explains the synergy at the molecular level.

CJC-1295: Persistent Growth Hormone Pulse Elevation

CJC-1295 is a synthetic GHRH analog with four amino acid substituents compared to native GHRH (1-29). These substituents make the peptide resistant to enzymatic degradation. As a result, CJC-1295 has a half-life of several hours — with the DAC variant even 6–8 days.

CJC-1295 has been extensively studied clinically. In two randomized, placebo-controlled, double-blind dose-escalation studies in healthy adults, GH plasma concentrations increased dose-dependently by a factor of 2 to 10 after a single injection — for at least 6 days. Simultaneously, IGF-1 concentrations increased by a factor of 1,5 to 3 for 9 to 11 days. Furthermore, after repeated doses, IGF-1 levels remained above baseline for up to 28 days. No serious adverse events were reported.

Furthermore, the preservation of pulsatile GH secretion with CJC-1295 use is scientifically relevant. Baseline GH levels (trough) increased by a factor of 7,5 — but the GH pulse frequency and amplitude remained unchanged. To this end, CJC-1295 increases IGF-1 production by increasing trough GH, not by disrupting physiological GH rhythms. This makes it a physiologically elegant research compound.

What Are Scientists Investigating at CJC-1295?

• Prolonged GHRH receptor stimulation and GH/IGF-1 elevation in healthy adults
• Preservation of pulsatile GH secretion patterns during sustained stimulation
• Pharmacokinetics of albumin-bound GHRH analogues (DAC variant)
• Body composition — fat metabolism and build-up of lean mass
• Cumulative IGF-1 response after repeated weekly administration

Scientific References — CJC-1295

• Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PubMed PMID 16352683
• Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–7. PubMed PMID 17018654
• Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):499–507. PubMed PMID 19386527

Ipamorelin: The Most Selective GH Secretagogue

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a ghrelin mimetic via the GHS-R1a receptor. Originally developed by Novo Nordisk, Ipamorelin distinguishes itself from all other GH-releasing peptides by its exceptional receptor selectivity. This makes it the preferred GHRP for research where pure GH effects are desired without confounders of cortisol or prolactin elevations.

The conclusive evidence for the selectivity of Ipamorelin comes from the groundbreaking study by Raun et al. (1998). While other GHRPs such as GHRP-2 and GHRP-6 caused significant increases in ACTH and cortisol, Ipamorelin did not. Cortisol and ACTH levels remained virtually identical after Ipamorelin administration to those after GHRH stimulation. This held true even at doses exceeding 200 times the ED50 for GH release. Furthermore, Ipamorelin left FSH, LH, prolactin, and TSH completely unaffected.

Furthermore, additional research shows that Ipamorelin also supports bone formation and muscle mass. In a rat study, Ipamorelin significantly reversed the decline in muscle strength and periosteal bone formation caused by glucocorticoids. This confirms a role in research into body composition and skeletal health, alongside purely GH-axis studies.

What Are Scientists Investigating in Ipamorelin?

• Selective GH release via GHS-R1a without an increase in ACTH or cortisol
• Synergistic GH pulse effect in combination with CJC-1295 and other GHRH analogs
• Bone density and periosteal bone formation in glucocorticoid models
• Sleep architecture and nocturnal GH secretion patterns
• Body composition — fat metabolism and muscle mass in preclinical models

Scientific References — Ipamorelin

• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–61. PubMed PMID 9849822
• Svensson J, et al. The growth hormone secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569–77. PubMed PMID 10828843
• Svensson J, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. J Bone Miner Res. 2001;16(11):2009–17. PubMed PMID 11735244
• Ishida J, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Commun. 2020;3(1):25–37. DOI 10.1002/rco2.9

Why CJC-1295 and Ipamorelin Together Form the Growth Starter Kit

The synergy in the Growth Starter Kit relies on two complementary receptor systems that reinforce each other. CJC-1295 activates the GHRH receptor via the cAMP/PKA signaling pathway. As a result, it stimulates GH gene transcription and expands the GH pulse window. Simultaneously, ipamorelin activates GHS-R1a via the phospholipase C pathway. Consequently, it triggers a sharp, selective GH release — precisely within the extended pulse window created by CJC-1295.

Moreover, Ipamorelin indirectly removes somatostatin inhibition in the hypothalamus. This is scientifically relevant because somatostatin is the primary “brake” on GH secretion. By reducing this inhibition, Ipamorelin further potentiates the effect of CJC-1295. As a result, the combined GH pulse is greater than the sum of the individual effects—a phenomenon that has been consistently reported in GH secretagogue research.

Specifically, this is the reason why CJC-1295 and Ipamorelin are consistently used together in the research community as the “standard” GH secretagogue combination. To this end, the Growth Starter Kit provides researchers with a beginner-friendly yet mechanistically sound dual-receptor protocol.

Growth Starter Kit vs. Phantom Stack — What Is the Difference?

Both the Growth Starter Kit and the Phantom Stack combine a GHRH analog with a GH-releasing peptide. However, there are two defining differences. First, the Growth Starter Kit uses Ipamorelin — the most selective GHRP, with minimal effect on cortisol and prolactin. The Phantom Stack uses GHRP-6 — a more potent but less selective GHRP that does significantly increase cortisol and prolactin levels.

Secondly, the Growth Starter Kit uses CJC-1295 (available as NO DAC or DAC), while the Phantom Stack specifically uses CJC-1295 DAC. Consequently, the Growth Starter Kit offers more flexibility in the dosing protocol. In short: the Growth Starter Kit is ideal for research into selective, pure GH effects. The Phantom Stack is suitable for research into the broader hormonal response, including cortisol interaction.

Research applications of the Growth Starter Kit

Researchers choose the CJC-1295 Ipamorelin bundle for the following study areas:

• Dual-receptor GH secretagogue study via GHRH and GHS-R1a pathways
• Synergistic GH pulse profiling — amplitude, frequency, and baseline level
• IGF-1 signaling pathways and downstream anabolic effects at the tissue level
• Body composition — lean mass, fat metabolism and nutrient partitioning
• Sleep architecture and nocturnal GH secretion study
• Bone density and skeletal health in muscle strength models
• Selective GHRP pharmacology without cortisol confounders

Who Is the Growth Starter Kit Intended For?

De Growth Starter Kit is ideally suited for:

• Researchers starting GH secretagogue research and requiring a clean hormonal profile
• Endocrinologists studying GHRH/GHRP synergy and pituitary pharmacology
• Sports scientists who research body composition, sleep, and GH-axis dynamics
• Biochemists who model IGF-1 signaling pathways and receptor crosstalk
• Anyone who wants to study pure GH effects without cortisol or prolactin interference.

Bundle Contents

• CJC-1295 — research-grade lyophilized peptide (≥98% purity, HPLC-verified)
• Ipamorelin — research-grade lyophilized peptide (≥98% purity, HPLC-verified)

Both peptides are supplied as lyophilized powder for reconstitution for research purposes. HPLC and mass spectrometry certificates from accredited independent laboratories are available upon request.

Frequently Asked Questions about the Growth Starter Kit

What is the difference between the CJC-1295 NO DAC and the CJC-1295 DAC?

CJC-1295 NO DAC (also known as Modified GRF 1-29) has a half-life of only 30 minutes. Consequently, it requires multiple daily injections for a consistent GH profile. CJC-1295 DAC contains a Drug Affinity Complex that covalently binds to serum albumin, extending the half-life to 6–8 days. This allows for once-weekly dosing. The choice depends on the desired dosing protocol in the study design.

Why is Ipamorelin better than GHRP-6 for beginner research?

Ipamorelin produces selective GH release without a significant increase in ACTH, cortisol, prolactin, or other hormones. GHRP-6 is more potent in terms of acute GH peak intensity but also increases cortisol and prolactin. Consequently, GHRP-6 introduces hormonal confounders that complicate research interpretation. For beginners and for research seeking to study pure GH effects, Ipamorelin is therefore the scientifically preferred choice.

Are CJC-1295 and Ipamorelin approved for human use?

No. CJC-1295 reached Phase 2 research but was discontinued. Ipamorelin never achieved full clinical registration. Neither peptide has approval from the FDA, EMA, or any other regulatory authority for therapeutic use. We offer this bundle exclusively for scientific laboratory research.

Complete Scientific References

1. Teichman SL, et al. Prolonged stimulation of GH and IGF-I by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799–805. PubMed PMID 16352683
2. Ionescu M, Frohman LA. Pulsatile GH secretion persists during CJC-1295. J Clin Endocrinol Metab. 2006;91(12):4792–7. PubMed PMID 17018654
3. Sackmann-Sala L, et al. GH/IGF-1 axis activation by CJC-1295. Growth Hormone IGF Res. 2009;19(6):499–507. PubMed PMID 19386527
4. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–61. PubMed PMID 9849822
5. Svensson J, et al. Ipamorelin and GHRP-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569–77. PubMed PMID 10828843
6. Svensson J, et al. Ipamorelin counteracts glucocorticoid-induced decrease in bone formation. J Bone Miner Res. 2001;16(11):2009–17. PubMed PMID 11735244
7. Ishida J, et al. Growth hormone secretagogues: history, mechanism, clinical development. JCSM Rapid Commun. 2020;3(1):25–37. DOI 10.1002/rco2.9

⚠ For research purposes only — Disclaimer: This product is intended exclusively for in vitro and laboratory researchIt is not intended for use in humans or animals, self-administration, diagnosis, treatment, or prevention of any disease or medical condition. CJC-1295 and Ipamorelin possess not regarding approval from the FDA, EMA or any equivalent regulatory authority for therapeutic use in humans. Researchers must comply with all applicable local laws, regulations, and institutional requirements. Keep out of reach of children. Handle in accordance with Good Laboratory Practice (GLP) guidelines.